Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma

NCT04094961 is registered in ClinicalTrials.gov with Omar Nadeem, MD as lead sponsor.

NCT NCT04094961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04094961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refractory Multiple Myeloma
Lead sponsor
Omar Nadeem, MD
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 18, 2019
Completion date
January 1, 2027
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, multiple myeloma in relapse